{"id":"empagliflozin-pill","safety":{"commonSideEffects":[{"rate":"8-13","effect":"Genital mycotic infections"},{"rate":"4-8","effect":"Urinary tract infections"},{"rate":"3-5","effect":"Polyuria"},{"rate":"2-4","effect":"Hypotension"},{"rate":"0.1-0.2","effect":"Diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL2107830","moleculeType":"Small molecule","molecularWeight":"450.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 is responsible for reabsorbing filtered glucose in the proximal tubule of the nephron. By blocking this transporter, empagliflozin prevents glucose reabsorption, allowing excess glucose to be excreted in the urine. This mechanism lowers blood glucose independently of insulin secretion and also provides cardiovascular and renal protective benefits through osmotic diuresis and reduced intraglomerular pressure.","oneSentence":"Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:43.611Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT05147090","phase":"PHASE4","title":"Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2022-01-02","conditions":"Chronic Hepatitis b, NAFLD, Cirrhosis","enrollment":106},{"nctId":"NCT07322237","phase":"PHASE4","title":"DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2026-01-01","conditions":"Cirrhotic Cardiomyopathy, Empagliflozin, Cardiometabolic Risk Factors","enrollment":400},{"nctId":"NCT04633005","phase":"PHASE2","title":"Polypill Strategy for Heart Failure With Reduced Ejection Fraction","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-11-15","conditions":"Heart Failure","enrollment":212},{"nctId":"NCT06260059","phase":"PHASE4","title":"Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease","status":"RECRUITING","sponsor":"Anita Saraf","startDate":"2024-09-17","conditions":"Adult Congenital Heart Disease, Heart Failure","enrollment":40},{"nctId":"NCT06507657","phase":"EARLY_PHASE1","title":"Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2024-12-12","conditions":"Hypertension, Cardiovascular Diseases","enrollment":80},{"nctId":"NCT04735042","phase":"","title":"SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2020-10-07","conditions":"Type 2 Diabetes, Urinary Tract Infections","enrollment":60},{"nctId":"NCT06862739","phase":"PHASE4","title":"Glycemic Control with Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination","status":"NOT_YET_RECRUITING","sponsor":"Nabiqasim Industries (Pvt) Ltd","startDate":"2025-04","conditions":"Diabetes Mellitus, Type 2 DM","enrollment":800},{"nctId":"NCT06632561","phase":"PHASE4","title":"Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus","status":"COMPLETED","sponsor":"Ashraf Wasfy Beshay Aziz","startDate":"2021-07-26","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":74},{"nctId":"NCT03193684","phase":"PHASE4","title":"Empagliflozin and Hepatic Glucose Metabolism","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2018-05-20","conditions":"Hepatic Glucose Metabolism","enrollment":72},{"nctId":"NCT03087773","phase":"PHASE3","title":"Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2017-05-11","conditions":"Acute Myocardial Infarction","enrollment":476},{"nctId":"NCT05885074","phase":"PHASE2","title":"Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2025-01-30","conditions":"Obesity, Weight Loss","enrollment":""},{"nctId":"NCT04642261","phase":"PHASE4","title":"Effect of Empagliflozin on Liver Fat in Non-diabetic Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2021-01-01","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":98},{"nctId":"NCT03151343","phase":"PHASE3","title":"SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk","status":"COMPLETED","sponsor":"Caroline M Kistorp","startDate":"2017-03-29","conditions":"Type2 Diabetes Mellitus","enrollment":92},{"nctId":"NCT03259490","phase":"PHASE1","title":"This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-08-31","conditions":"Healthy","enrollment":30},{"nctId":"NCT03629054","phase":"PHASE1","title":"This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-08-27","conditions":"Healthy","enrollment":30},{"nctId":"NCT02833415","phase":"PHASE4","title":"Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-03","conditions":"Obesity, Visceral","enrollment":40},{"nctId":"NCT04195243","phase":"PHASE3","title":"Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Centro Universitario de Ciencias de la Salud, Mexico","startDate":"2019-12-02","conditions":"Type 2 Diabetes Mellitus","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Jardiance","Empagliflozin"],"phase":"phase_3","status":"active","brandName":"Empagliflozin Pill","genericName":"Empagliflozin Pill","companyName":"Centro Universitario de Ciencias de la Salud, Mexico","companyId":"centro-universitario-de-ciencias-de-la-salud-mexico","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels. Used for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}